Design and rationale for the Patient and Provider Assessment of Lipid Management (PALM) registry
Design and rationale for the Patient and Provider Assessment of Lipid Management (PALM) registry
复制标题
DOI：
10.1016/j.ahj.2015.08.002
复制
发表时间：
2015-11-01
影响因子：
4.8
通讯作者：
Peterson, Eric
中科院分区：
文献类型：
--
作者：
Navar, Ann Marie;Wang, Tracy Y.;Peterson, Eric
背景：尽管在诊断和治疗方面有所改进，但美国成年人中高脂血症的患病率仍然很高。自新的血脂指南发布以来，关于治疗模式和患者对心血管疾病风险的看法的数据有限。目的Palm登记的目标是评估在全国具有代表性的社区诊所队列中接受护理的成年人使用降脂治疗的当代模式，确定不同血脂指南治疗的一致性，确定影响降脂治疗使用的因素，包括患者报告的他汀类药物不耐受，并评估患者和提供者对降低心血管风险目标的知识。研究设计Palm登记将从全美175个心脏科、初级保健和内分泌学实践中招募7500名可能被考虑接受降脂治疗的患者。在这个横断面的观察性登记中，将使用一个基于平板电脑的新型平台来收集患者报告的关于降低心血管风险和血脂管理的知识、态度和信念。图表摘要和核心实验室血脂水平将描述当前的血脂管理。提供商调查将评估对当前降脂目标的看法以及最佳降低心血管风险的障碍。结论Palm注册将允许更好地了解当前的实践模式、患者经验以及患者和提供商对降低心血管疾病风险的胆固醇管理的态度。这些数据可以用来更好地了解护理方面的差距，并设计有针对性的干预措施，以提高降低心血管风险的降脂疗法的接受度。
Background Despite improvements in diagnosis and treatment, the prevalence of hyperlipidemia among adults in the United States remains high. Data are limited on treatment patterns and patient perceptions of cardiovascular disease risk since the release of new lipid guidelines.Objectives The objectives of the PALM registry are to assess contemporary patterns of lipid-lowering therapy use among adults receiving care in a nationally representative cohort of community clinics, determine consistency of treatment with varying lipid guidelines, identify factors affecting use of lipid-lowering therapy including patient-reported statin intolerance, and assess patient and provider knowledge of cardiovascular risk reduction goals.Study Design The PALM registry will enroll 7,500 patients likely to be considered for lipid-lowering therapy from 175 cardiology, primary care, and endocrinology practices across the United States. In this cross-sectional, observational registry, a novel tablet-based platform will be used to collect patient-reported knowledge, attitudes, and beliefs regarding cardiovascular risk reduction and lipid management. Chart abstraction and core laboratory lipid levels will describe current lipid management. Provider surveys will assess perception of current lipid-lowering goals and barriers to optimal cardiovascular risk reduction.Conclusion The PALM registry will allow for better understanding of current practice patterns, patient experiences, and patient and provider attitudes toward cholesterol management for cardiovascular disease risk reduction. These data can be used to better understand gaps in care and design targeted interventions to improve uptake of lipid-lowering therapies for cardiovascular risk reduction.